OR-AIRSHIP
16.5.2019 15:02:09 CEST | Business Wire | Press release
Customer engagement company Airship today announced May and June dates and locations for its 2019 Customer Engagement Forum , a year-long global event series. These interactive sessions feature leaders from many of the world's leading brands discussing their plans and practices for customer engagement (CX) in a digital world — arming marketers with proven strategies, research and techniques to connect with customers in smarter, faster, and more effective ways.
Dubbed ELEVATE, the educational series will kick-off in Santa Monica on May 21, 2019 and San Francisco on May 30, 2019. In June, the forum series will come to Paris , Chicago , New York , Amsterdam and London . Seats are limited; those interested in attending should reserve their spot using the city-specific links above. Additional cities and dates will be announced later this year.
Featuring a unique collection of speakers in each city, the series will focus on the growing focus on customer experience (CX) as the key driver of many companies’ growth and competitive strategies. Among topics such as CX best practices and innovation, the program will also include a discussion of building a business case for the value of better customer experience (CX).
According to Gartner, “Today, slightly more than two-thirds of marketers responsible for CX say their companies compete on the basis of CX. In two years, this expectation rises even further, with 81% of respondents anticipating their companies will do so.” (Gartner, Customer Experience in Marketing Survey 2017: Greater Expectations, Greater Challenges, Augie Ray, Jane-Anne Mennella, Simon Yates, Refreshed April 9, 2019, Published 5 October 2017).
Customer Engagement Forum attendees will gain a sharper understanding of what’s at stake when it comes to getting customer engagement right — learning about the CX trends experts are watching, as well as the CX tech stack and common team structures. Beyond a notebook full of ideas to leapfrog the competition and crush their KPIs, attendees will gain stats to build a business case for the value of better CX to grow their budgets and their careers.
“Forrester analyzed the correlation between CX quality and revenue growth for companies in five industries ... companies with superior CX grew revenues five times faster on average than their competitors with inferior CX. And this is a global phenomenon” (Forrester Research, Inc., “Improving CX Through Business Discipline Drives Growth,” June 19, 2017; Updated March 26, 2018).
Companies speaking at Customer Engagement Forum events include AccuWeather, AMC Theatres, Expensify, Footlocker, France TV, GSN Games, Tribune Publishing, Turner Sports and Zillow, with more to come.
“Today’s fastest-growing brands separate themselves from the pack by providing unique experiences that deliver surprising convenience and delight to their customers,” said Mike Stone, SVP of Marketing, Airship. “The Airship Customer Engagement Forum provides marketers an incredible opportunity to learn successful CX strategies from leading brands, as well as the programs and tactics to put them into place.”
For more information on Airship’s Customer Engagement Forum 2019, or to register, please visit forum.airship.com .
About Airship
Marketing and digital experience teams at thousands of the world’s most admired companies rely on Airship’s Customer Engagement Platform to create deeper connections with customers by delivering incredibly relevant, orchestrated messages on any channel.
Founded in 2009 as a pioneer in push notifications, Airship now gives brands the user-level data, engagement channels, AI orchestration and services they need to deliver push notifications, emails, SMS, in-app messages, mobile wallet cards and more to exactly the right person in exactly the right moment — building trust, boosting engagement, driving action and growing value.
Learn more about our Customer Engagement Platform , read our blog or follow us on Twitter , LinkedIn and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190516005238/en/
Contact:
North America: Dave Struzzi Bateman Group +1 415-697-2560 airship@bateman-group.com
Corey Gault Airship +1 503-206-9164 corey@airship.com
EMEA: Nicolas Vitre Airship +33 1 44 56 88 21 +33 6 88 04 76 86 nicolas.vitre@airship.com
UK: Lucinda Layton Hotwire UK +44 20 7608 2500 Airship@hotwireglobal.com
France: Marion Fajgenbaum / Marine Cressot Hotwire France +33 14 312 55 68 / 69 AirshipFR@hotwireglobal.com
Germany: Julia da Silva Bastos Hotwire Germany +49 89 2620 81 89 airshipde@hotwireglobal.com
Spain: Beatriz Pérez Hotwire Spain +34 917 44 1265 beatriz.perez@hotwireglobal.com
Italy: Sara Tetti Hotwire Italy +39 349 5788052 AirshipIT@hotwireglobal.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom